Sale

Tuberculosis Treatment Market

Global Tuberculosis Treatment Market Share, Size, Trends, Analysis, Forecast: By Disease Type: Active Tuberculosis, Latent Tuberculosis; By Therapy Type: First Line Therapy, Second Line Therapy; By Route of Administration: Oral, Parenteral, Others; By Dosage Form; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Global Tuberculosis Treatment Market Outlook

The global tuberculosis treatment market reached a value of about USD 1.74 billion in 2023. The market is expected to grow at a CAGR of 7.57% during the forecast period of 2024-2032 to attain a value of USD 3.37 billion by 2032. The growth of the market is driven by the rising favourable government policies to increase demand for tuberculosis (TB) diagnostics.

 

Tuberculosis Treatment Market: Introduction and Insights

Tuberculosis (TB) is an infectious disease that primarily affects the lungs. Tuberculosis bacteria spread from person to person via tiny droplets released into the air by coughs and sneezes, it can also attack other organs, such as the kidneys, spine, and brain. Not everyone who is infected with tuberculosis bacteria (germs) becomes ill. There are two kinds of tuberculosis:

 

  • Latent tuberculosis infection, in which the TB germs live in the body but do not lead to illness.
  • Tuberculosis disease (active TB), in which the patient becomes ill as a result of the TB germs. Antibiotics can almost always cure tuberculosis, however, if not treated properly, it can be fatal.

 

The prevalence of tuberculosis is rapidly rising and is likely to continue rising in the coming years as well, driven by the rising number of smokers. Majority of people who have TB germs in their bodies do not develop TB disease, instead, they have latent tuberculosis infection. Tuberculosis can spread when a person with active TB disease sneezes, coughs, sings, talks, or even laughs, anything that involves releasing germs into the air. While latent TB does not get transmitted, active pulmonary infection is highly contagious.

 

Inactive tuberculosis does not cause symptoms; however, they can be diagnosed with a positive skin reaction test or blood test. Active TB patients may exhibit any of the following symptoms:

 

  • Coughing Fits
  • Chest Pain
  • Blood or Sputum Coughing (Mucus)
  • Weakness Or Fatigue
  • Appetite Loss
  • Loss Of Weight
  • Chills
  • Fever
  • Sweating

 

There are two types of tuberculosis screening tests, namely Mantoux Tuberculin Skin Test (TST) and Interferon-Gamma Release Assay (blood test) (IGRA).

 

A healthcare provider will inject a small amount of purified protein derivative (PPD) under the skin of the forearm for the TST.

 

Additional tests to determine whether an infection is active or whether the lungs are infected include sputum and lung fluid testing, X-ray of the chest, and/or CT scans (computed tomography).

 

tuberculosis treatment market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

According to the market research report, the market can be categorised into the following segments:

 

Market Breakup by Disease Type

  • Active Tuberculosis
  • Latent Tuberculosis

 

Market Breakup by Therapy Type

  • First Line Therapy
  • Second Line Therapy

 

Market Breakup by Route of Administration

  • Oral
  • Parenteral
  • Others

 

Market Breakup by Dosage Form

  • Tablets
  • Capsules
  • Injections
  • Others

 

Market Breakup by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

 

tuberculosis treatment market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Breakup by Region

  • North America
    • United States of America
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others

 

Global Tuberculosis Treatment Market: Epidemiology

More than 1.7 billion people (roughly 22% of the world's population) are estimated to be infected with tuberculosis. The global incidence of tuberculosis peaked around 2003 and appears to be slowly declining. According to the World Health Organization (WHO), 9.9 million people became ill with tuberculosis (TB) in 2020, with 1.5 million deaths.

 

As per the records, in 2021, there was 7,860 tuberculosis cases reported in the United States. The incidence rate in the United States has reached close to 2.4 cases per 100,000 people.

 

tuberculosis treatment market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Global Tuberculosis Treatment Market- Therapeutic Landscape

Antibiotics are typically used to treat tuberculosis (TB) in the initial treatment, which goes on for several months. The standard treatment is 6 months of antibiotics (isoniazid and rifampicin). For the first 2 months of the 6-month treatment period, 2 additional antibiotics (pyrazinamide and ethambutol) are administered. Extrapulmonary tuberculosis (TB that occurs outside the lungs) can be treated with the same antibiotic combination as pulmonary tuberculosis.

 

If tuberculosis is in areas such as the brain or the sac surrounding the heart (pericardium), the patient may be given a corticosteroid such as prednisolone, alongside the antibiotics for several weeks. This will aid in the reduction of swelling in the affected areas.

 

If latent tuberculosis is thought to be drug-resistant, it is not always treated. If this is the case, the patient may be monitored on a regular basis to ensure that the infection does not become active. For latent tuberculosis patients, the most common prescription includes Rifampicin and isoniazid in combination for 3 months, and Isoniazid alone for 6 months.

 

Global Tuberculosis Treatment Market Scenario

The increased public-private partnership, favourable government policies to boost the demand for tuberculosis (TB) diagnostics, and the rising incidence of tuberculosis in high-burden countries are the factors driving the global tuberculosis treatment market.

 

In the forecast year, the limitations of existing tuberculosis diagnostics will impede the market growth.

 

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the global tuberculosis treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

 

  • Johnson And Johnson Services, Inc.
  • Lupin Ltd
  • Novartis AG
  • Macleods Pharmaceuticals Ltd.
  • Otsuka Pharmaceutical Co., Ltd
  • Pfizer Inc.
  • AstraZeneca Plc
  • Cipla Ltd
  • Alkem Laboratories Ltd
  • Eli Lilly And Company
  • F. Hoffmann-La Roche Ltd.
  • Viatris Inc. (Mylan N.V.)
  • Teva Pharmaceutical Industries, Ltd.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Disease Type
  • Therapy Type
  • Route of Administration
  • Dosage Form
  • Distribution Channel
  • Region
Breakup by Disease Type
  • Active Tuberculosis
  • Latent Tuberculosis
Breakup by Therapy Type
  • First Line Therapy
  • Second Line Therapy
Breakup by Route of Administration
  • Oral
  • Parenteral
  • Others
Breakup by Dosage Form
  • Tablets
  • Capsules
  • Injections
  • Others
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis 
  • Porter's Five Forces Analysis 
  • Key Indicators for Demand
  • Key Indicators for Price
  • Industry Events, Initiatives, and Trends
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Johnson and Johnson Services, Inc.
  • Lupin Ltd
  • Novartis AG
  • Macleods Pharmaceuticals Ltd.
  • Otsuka Pharmaceutical Co., Ltd
  • Pfizer Inc.
  • AstraZeneca Plc
  • Cipla Ltd
  • Alkem Laboratories Ltd
  • Eli Lilly And Company
  • F. Hoffmann-La Roche Ltd.
  • Viatris Inc. (Mylan N.V.)
  • Teva Pharmaceutical Industries, Ltd.

 

Our Top Selling Reports

eHealth Market

Ascites Market

Heparin Market

United States Lancets Market

Erythema Market

Cryostat Market

Eye Care Market

Hospital Market

Dialysis Market

Tele-ICU Market

 

Tuberculosis Treatment Market Report Snapshots

Tuberculosis Treatment Market Size

Tuberculosis Treatment Companies

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Tuberculosis Overview

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Tuberculosis Treatment Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Tuberculosis Epidemiology (2016-2031)
    5.3    Europe Tuberculosis Epidemiology (2016-2031)
    5.4    Asia-Pacific Tuberculosis Epidemiology (2016-2031)
    5.5    Latin America Tuberculosis Epidemiology (2016-2031)
    5.6    Middle East & Africa Tuberculosis Epidemiology (2016-2031)
6    Global Tuberculosis Treatment Market Overview
    6.1    Global Tuberculosis Treatment Market Historical Value (2017-2023) 
    6.2    Global Tuberculosis Treatment Market Forecast Value (2024-2032)
7    Global Tuberculosis Treatment Market Landscape
    7.1    Tuberculosis Treatment: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Tuberculosis Treatment: Product Landscape
        7.2.1    Analysis by Product
        7.2.2    Analysis by End User
8    Tuberculosis Treatment Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Global Tuberculosis Treatment Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Global Tuberculosis Treatment Market Segmentation
    11.1    Global Tuberculosis Treatment Market by Disease Type
        11.1.1    Market Overview
        11.1.2    Active Tuberculosis
        11.1.3    Latent Tuberculosis
    11.2    Global Tuberculosis Treatment Market by Therapy Type
        11.2.1    Market Overview
        11.2.2    First Line Therapy
        11.2.3    Second Line Therapy 
    11.3    Global Tuberculosis Treatment Market by Route of Administration
        11.3.1    Market Overview
        11.3.2    Oral
        11.3.3    Parenteral
        11.3.4    Others
    11.4    Global Tuberculosis Treatment Market by Dosage Form
        11.4.1    Market Overview
        11.4.2    Tablets 
        11.4.3    Capsules 
        11.4.4    Injections
        11.4.5    Others
    11.5    Global Tuberculosis Treatment Market by Distribution Channel
        11.5.1    Market Overview
        11.5.2    Hospital Pharmacy
        11.5.3    Retail Pharmacy
        11.5.4    Online Pharmacy
    11.6    Global Tuberculosis Treatment Market by Region
        11.6.1    Market Overview
        11.6.2    North America
        11.6.3    Europe 
        11.6.4    Asia Pacific
        11.6.5    Latin America
        11.6.6    Middle East and Africa
12    North America Tuberculosis Treatment Market
    12.1    Market Share by Country
    12.2    United States of America
    12.3    Canada
13    Europe Tuberculosis Treatment Market
    13.1    Market Share by Country
    13.2    United Kingdom
    13.3    Germany
    13.4    France
    13.5    Italy
    13.6    Others
14    Asia Pacific Tuberculosis Treatment Market
    14.1    Market Share by Country
    14.2    China
    14.3    Japan
    14.4    India
    14.5    ASEAN
    14.6    Australia
    14.7    Others
15    Latin America Tuberculosis Treatment Market
    15.1    Market Share by Country
    15.2    Brazil
    15.3    Argentina
    15.4    Mexico
    15.5    Others
16    Middle East and Africa Tuberculosis Treatment Market
    16.1    Market Share by Country
    16.2    Saudi Arabia
    16.3    United Arab Emirates
    16.4    Nigeria
    16.5    South Africa
    16.6    Others
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Patent Analysis
    18.1    Analysis by Type of Patent
    18.2    Analysis by Publication year
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Patent Age
    18.5    Analysis by CPC Analysis
    18.6    Analysis by Patent Valuation 
    18.7    Analysis by Key Players
19    Grants Analysis
    19.1    Analysis by year
    19.2    Analysis by Amount Awarded
    19.3    Analysis by Issuing Authority
    19.4    Analysis by Grant Application
    19.5    Analysis by Funding Institute
    19.6    Analysis by NIH Departments
    19.7    Analysis by Recipient Organization
20    Clinical Trials Analysis
    20.1     Analysis by Trial Registration Year
    20.2    Analysis by Trial Status
    20.3    Analysis by Trial Phase
    20.4    Analysis by Therapeutic Area
    20.5    Analysis by Geography
21    Funding and Investment Analysis
    21.1    Analysis by Funding Instances
    21.2    Analysis by Type of Funding
    21.3    Analysis by Funding Amount
    21.4    Analysis by Leading Players
    21.5    Analysis by Leading Investors
    21.6    Analysis by Geography
22    Partnership and Collaborations Analysis
    22.1    Analysis by Partnership Instances
    22.2    Analysis by Type of Partnership
    22.3    Analysis by Leading Players
    22.4    Analysis by Geography
23    Supplier Landscape
    23.1    Johnson and Johnson Services, Inc.
        23.1.1    Financial Analysis
        23.1.2    Product Portfolio
        23.1.3    Demographic Reach and Achievements
        23.1.4    Mergers and Acquisitions
        23.1.5    Certifications
    23.2    Lupin Ltd
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications
    23.3    Novartis AG
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4    Macleods Pharmaceuticals Ltd.
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5    Otsuka Pharmaceutical Co., Ltd
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    Pfizer Inc.
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    AstraZeneca Plc
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    Cipla Ltd
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    Alkem Laboratories Ltd
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    Eli Lilly And Company
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications 
    23.11    F. Hoffmann-La Roche Ltd.
        23.11.1    Financial Analysis
        23.11.2    Product Portfolio
        23.11.3    Demographic Reach and Achievements
        23.11.4    Mergers and Acquisitions
        23.11.5    Certifications
    23.12    Viatris Inc. (Mylan N.V.)
        23.12.1    Financial Analysis
        23.12.2    Product Portfolio
        23.12.3    Demographic Reach and Achievements
        23.12.4    Mergers and Acquisitions
        23.12.5    Certifications
    23.13    Teva Pharmaceutical Industries, Ltd.
        23.13.1    Financial Analysis
        23.13.2    Product Portfolio
        23.13.3    Demographic Reach and Achievements
        23.13.4    Mergers and Acquisitions
        23.13.5    Certifications
24    Tuberculosis Treatment - Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Company Competitiveness Analysis (Additional Insight)

    26.1    Very Small Companies
    26.2    Small Companies
    26.3    Mid-Sized Companies
    26.4    Large Companies
    26.5    Very Large Companies
27    Payment Methods (Additional Insight)
    27.1    Government Funded
    27.2    Private Insurance
    27.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The global tuberculosis treatment market reached a value of about USD 1.74 billion in 2023, rising favourable government policies to increase demand for tuberculosis (TB) diagnostics.

The market is expected to grow at a CAGR of 7.57% during the forecast period of 2024-2032 to attain a value of USD 3.37 billion by 2032.

The increased public-private partnership, favourable government policies to boost the demand for tuberculosis (TB) diagnostics, and the rising incidence of tuberculosis in high-burden countries are the key factors driving the global tuberculosis treatment market growth.

Tuberculosis can be categorized into two types- active tuberculosis and latent tuberculosis.

The treatment types can be divided into first line therapy and second line therapy.

The route of administration includes oral and parenteral, among others.

The dosage types can be categorized into tablets, capsules, and injections, among others.

The distribution channels used in the market include hospital pharmacy, retail pharmacy, and online pharmacy.

The key players in the market include Johnson and Johnson Services, Inc., Lupin Ltd, Novartis AG, Macleods Pharmaceuticals Ltd., Otsuka Pharmaceutical Co., Ltd, Pfizer Inc., AstraZeneca Plc, Cipla Ltd, Alkem Laboratories Ltd, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Viatris Inc. (Mylan N.V.), and Teva Pharmaceutical Industries, Ltd., among others.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER